Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies.
暂无分享,去创建一个
[1] Gary D Bader,et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma , 2014, Nature.
[2] R. Beroukhim,et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition , 2014, Nature Medicine.
[3] Gabor T. Marth,et al. Novel somatic and germline mutations in intracranial germ cell tumours , 2014, Nature.
[4] R. McLendon,et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas , 2014, Nature Genetics.
[5] M. Shago,et al. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity , 2014, Acta Neuropathologica.
[6] David T. W. Jones,et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing , 2014, Nature.
[7] J. Olson,et al. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. , 2014, Cancer cell.
[8] Stephen Yip,et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma , 2014, Nature Genetics.
[9] Liliana Goumnerova,et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma , 2014, Nature Genetics.
[10] Amar Gajjar,et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.
[11] Stefan M. Pfister,et al. The WIP1 Oncogene Promotes Progression and Invasion of Aggressive Medulloblastoma Variants , 2014, Oncogene.
[12] Roland Eils,et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. , 2014, Cancer cell.
[13] Michael Brudno,et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations , 2014, Nature Genetics.
[14] Li Ding,et al. C11orf95-RELA fusions drive oncogenic NF-κB signaling in ependymoma , 2014, Nature.
[15] Gary D Bader,et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy , 2014, Nature.
[16] A. Otsuka,et al. Mutually exclusive mutations of KIT and RAS are associated with KIT mRNA expression and chromosomal instability in primary intracranial pure germinomas , 2014, Acta Neuropathologica.
[17] John Y. K. Lee,et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas , 2014, Nature Genetics.
[18] Volker Hovestadt,et al. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity , 2013, Acta Neuropathologica.
[19] Nada Jabado,et al. Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR , 2013, Nature Genetics.
[20] R. Beroukhim,et al. BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma , 2013, Clinical Cancer Research.
[21] David T. W. Jones,et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. , 2013, Cancer cell.
[22] R. Young,et al. Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.
[23] Scott L. Pomeroy,et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma , 2013, Acta Neuropathologica.
[24] Barbara S. Paugh,et al. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. , 2013, Cancer research.
[25] H. Kimura,et al. JMJD1C, a JmjC Domain-Containing Protein, Is Required for Long-Term Maintenance of Male Germ Cells in Mice1 , 2013, Biology of reproduction.
[26] J. Huse,et al. Evaluation of Histone 3 Lysine 27 Trimethylation (H3K27me3) and Enhancer of Zest 2 (EZH2) in Pediatric Glial and Glioneuronal Tumors Shows Decreased H3K27me3 in H3F3A K27M Mutant Glioblastomas , 2013, Brain pathology.
[27] J. Schmid,et al. The complexity of NF-κB signaling in inflammation and cancer , 2013, Molecular Cancer.
[28] Roland Eils,et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.
[29] B. Garcia,et al. Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma , 2013, Science.
[30] A. Ashworth,et al. Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. , 2013, Cancer discovery.
[31] Sabine Mueller,et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. , 2013, Genes & development.
[32] Liliana Goumnerova,et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1 , 2013, Proceedings of the National Academy of Sciences.
[33] Heather L. Mulder,et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.
[34] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.
[35] J. Korbel,et al. Criteria for Inference of Chromothripsis in Cancer Genomes , 2013, Cell.
[36] Steven J. M. Jones,et al. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma , 2013, Acta Neuropathologica.
[37] David T. W. Jones,et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas , 2013, Acta Neuropathologica.
[38] Scott L. Pomeroy,et al. Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.
[39] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[40] N. Smoll,et al. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children , 2012, Journal of Clinical Neuroscience.
[41] David T. W. Jones,et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.
[42] D. Brat,et al. Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.
[43] Hideo Nakamura,et al. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. , 2012, The Lancet. Oncology.
[44] Kristian Cibulskis,et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. , 2012, The Journal of clinical investigation.
[45] Matthew J. Betts,et al. Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.
[46] Jill P. Mesirov,et al. MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.
[47] P. Northcott,et al. Molecular subgroups of medulloblastoma , 2012, Expert review of neurotherapeutics.
[48] Elaine R. Mardis,et al. Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.
[49] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[50] David T. W. Jones,et al. Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations , 2012, Cell.
[51] Li Ding,et al. Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.
[52] David T. W. Jones,et al. MAPK pathway activation in pilocytic astrocytoma , 2011, Cellular and Molecular Life Sciences.
[53] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.
[54] T. Möröy,et al. Growth factor independence 1 (Gfi1) as a regulator of lymphocyte development and activation. , 2011, Seminars in immunology.
[55] W. Yung,et al. An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. , 2011, Cancer cell.
[56] Gary D Bader,et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. , 2011, Cancer cell.
[57] Amar Gajjar,et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma , 2010, Nature.
[58] B. Scheithauer,et al. Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes , 2010, Acta Neuropathologica.
[59] Jeremy Stinson,et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. , 2009, The New England journal of medicine.
[60] V. P. Collins,et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. , 2009, Cancer cell.
[61] B. Hinkes,et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. , 2009, European journal of cancer.
[62] Paul A. Northcott,et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma , 2009, Nature Genetics.
[63] T. Merchant,et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. , 2009, The Lancet. Oncology.
[64] Tomokazu Fukuda,et al. BMP type I receptor inhibition reduces heterotopic ossification , 2008, Nature Medicine.
[65] David T. W. Jones,et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.
[66] B. Scheithauer,et al. The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.
[67] T. Merchant,et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.
[68] Amar Gajjar,et al. Radial glia cells are candidate stem cells of ependymoma. , 2005, Cancer cell.
[69] J. Biegel,et al. Immunohistochemical Analysis of hSNF5/INI1 in Pediatric CNS Neoplasms , 2004, The American journal of surgical pathology.
[70] S. Hirohashi,et al. Short Communication Craniopharyngiomas of Adamantinomatous Type Harbor -Catenin Gene Mutations , 2002 .
[71] T. Poggio,et al. Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.
[72] E. Bouffet,et al. Chemotherapy for intracranial ependymomas , 1999, Child's Nervous System.
[73] Olivier Delattre,et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer , 1998, Nature.
[74] C. James,et al. Sporadic medulloblastomas contain PTCH mutations. , 1997, Cancer research.
[75] Michael Dean,et al. Mutations of the Human Homolog of Drosophila patched in the Nevoid Basal Cell Carcinoma Syndrome , 1996, Cell.
[76] R. Myers,et al. Human Homolog of patched, a Candidate Gene for the Basal Cell Nevus Syndrome , 1996, Science.
[77] Steven J. M. Jones,et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.
[78] In Ho Choi,et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva , 2006, Nature Genetics.
[79] David Hogg,et al. Mutations in SUFU predispose to medulloblastoma , 2002, Nature Genetics.
[80] J. Biegel,et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. , 1999, Cancer research.